| Literature DB >> 30845848 |
U Milenkovic1, Mm Ilg2, S Cellek2, M Albersen1.
Abstract
INTRODUCTION: Finding novel medical treatment for Peyronie's disease (PD) has suffered from similar limitations and difficulties as other fibrotic diseases.Areas covered: Underlying fibrosis, there is a vastly complex intertwining of several pathways. Focusing on a single target during antifibrotic drug development has not led to the development of many efficacious drugs, especially in PD. Inhibiting one cog in this large machinery usually leads to activation of compensatory mechanisms.Expert opinion: Novel strategies in drug discovery such as phenotypical drug screening and gene expression profiling technologies could provide a solution for this impasse.Entities:
Keywords: Peyronie’s disease; extracellular matrix; macrophages; medical treatment; myofibroblasts; phenotypical drug screening
Mesh:
Year: 2019 PMID: 30845848 DOI: 10.1080/14728214.2019.1591370
Source DB: PubMed Journal: Expert Opin Emerg Drugs ISSN: 1472-8214 Impact factor: 4.191